Skip to main content
Emma Thomas-Jones

Dr Emma Thomas-Jones

(she/her)

cymraeg
Welsh speaking
Users
Available for postgraduate supervision

Teams and roles for Emma Thomas-Jones

  • Principal Research Fellow and Deputy Director Infections Inflammation and Immunity Division

    School of Medicine

Overview

I am a Principal Research Fellow and Deputy Director for Infections, Inflammation & Immunity Research Division at the Centre for Trials Research .

My research areas are in common infections in primary care (e.g. UTI), biomarkers for infections and sepsis. I conduct evidence-based research testing the effectiveness of interventions with the aim of reducing antibiotic resistance.

I have extensive knowledge and experience in clinical trial methodology, trial conduct and research governance.

Publication

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

Cynadleddau

Erthyglau

Research

Research Interests

  • Infections, Inflammation and Immunity
  • Biomarkers and Point of Care Devices
  • Sepsis
  • Antimicrobial stewardship

Grants

I have been awarded >£32m in grant funding across 24 grants, including £2m as co-chief investigator.

Research grants (most recent first), with my specific role in bold:

2024

  • Abbott and Thomas-Jones, et al. EXamining antibiotics for ulCerated skIn cancer Surgical Excision (EXCISE). NIHR HTA. £1.5M (Co-Chief Investigator).
  • Roberts, Roland, and Cathie et al. A randomised trial of aminophylline, magnesium sulfate or salbutamol intravenous therapy for acute severe asthma in children and young people. NIHR HTA. £2.3M (Co-applicant, Lead for Trial Management).

2023

  • Harding, et al. IntraVESical Preparations for Recurrent Urinary TrAct Infection Prevention (The VESPER Trial): a multi-arm, multi-site open label randomised superiority trial. NIHR HTA. £2.1M (CTR Principal Investigator)
  • Kotecha, et al. Bacterial mucosal immunotherapy for prevention of wheeze in preterm born infants (BALLOON Trial). NIHR/MRC EME. £2.7M (Co-applicant).
  • Pallmann P and Carrol E, et al. Platform randomised evaluation of clinical outcomes using novel technologies to optimise antimicrobial therapy (PROTECT). NIHR HTA. £205K (CTR Principal Investigator).

2021

  • Mark Tuthill et al. RAPID PROTECTION: an adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus AztraZeneca, £3.1M (CTR principal investigator).

2020

  • Sandoe J and Carrol ED, et al. Procalcitonin: Evaluation of Antibiotic use in COVID-19 Hospitalised patients (The PEACH Study). NIHR COVID Rapid Recovery Call. £731,859. (CTR Principal Investigator)
  • Phillips R, Thomas-Jones E, et al. COVID-19 public experiences in Wales: A longitudinal mixed-methods study of attitudes, beliefs, and behaviour in response to the coronavirus pandemic (COPE Cymru). Ser Cymru Call for COVID-19 Research. £130K. (Co-chief Investigator).
  • Bosanquet D, et al. PrEdiction of Risk and Communication of outcomE followIng major lower limb amputation- a collaboratiVE study (PERCEIVE). Health and Care Research Wales (Research for Patient and Public Benefit RfPPB), £229,225 (Co-applicant).
  • Carrol ED, Thomas-Jones E, et al. - MR-Pro-adrenomedullin (MR-proADM) and ImmunoExpert Evaluation of procalcitonin-guided antibiotic duration in Children with Infection for Stratification of Effectiveness (PRECISE). NIHR Efficacy and Mechanism Evaluation (EME). £385,451. (Co-Chief Investigator).
  • Edwards AE, et al. Health Care Research Wales (Welsh Government Infrastructure Funding). PRIME Centre Infrastructure renewal. £4.8M (Co-Applicant).

2019

  • Hood K, et al. Health and Care Research Wales. Centre for Trials Research Infrastructure renewal. £2.5M (Co-applicant).
  • Solomon T, et al. Enceph-IG - Intravenous Immunoglobulin in Autoimmune Encephalitis in Adults: A Randomised Double-Blind Placebo-Controlled Trial. NIHR/MRC EME. £2.4M (CTR Principal Investigator).
  • Kotecha S, et al. AZithromycin ThErapy for Chronic lung disease (AZTEC): A randomised, placebo-controlled trial of azithromycin for the prevention of chronic lung disease of prematurity in preterm infants. NIHR HTA. £2,518,929. (Co-applicant).
  • French N, et al. PROcalcitonin and NEWS evaluation for Timely identification of sepsis and Optimal use of antibiotics in the Emergency Department (PRONTO). NIHR HTA. £1,964,286. (CTR Principal Investigator).

2018

  • Ingram J, et al. Management of Hidrandenitis Suppurativa (THESEUS). NIHR HTA. £629,000. (CTR Principal Investigator).

2017

  • Carrol ED, et al. Biomarker-guided duration of Antibiotic Treatment in Children Hospitalised with confirmed or suspected bacterial infection (BATCH). NIHR HTA. £1.5M. (CTR Principal Investigator).
  • Edwards AE, Harding C. et al. Primary care management of lower urinary tract symptoms in men: Development and validation of a diagnostic and decision-making aid (PRIMUS). NIHR HTA. £1.6M. (CTR Principal Investigator).

2016

  • Twine C, Bosanquet, D, et al. A phase II clinical trial examining the use of perineural catheters after major lower limb amputation in adults with critical limb ischaemia (PLACEMENT Feasibility Study). Health and Care Research Wales (RfPPB). £210,552 (CTR Principal Investigator).

2015

·       Clinical Trials Unit Infrastructure funding. Health and Care Research Wales. £2.9 M. (Co-applicant).

2014

·       Powell C, et al. Paediatric early warning system (PEWS): Utilisation and Mortality Avoidance (PUMA). NIHR Health Service & Delivery Research (HS&DR) £1.9 M. (Co-applicant).

2013

·       Ingram J, et al. Supporting antibiotic prescribing decisions for diabetic foot ulcer infections: an investigation of the diagnostic accuracy of inflammatory biomarkers. Health and Care Research Wales RfPPB £195,920. (Co-applicant).

2011

·       Butler C, et al. Oral Steroids for the Resolution of otitis media with effusion (OME) In Children (OSTRICH) NIHR HTA£1.3 M. (Co-applicant).

Biography

Education and qualifications

  • 1997: PhD "The estimation of circulating plasma volume using fluorescently labelled hydroxyethyl starch”. School of Molecular and Medical Biosciences, University of Wales, Cardiff.
  • 1993: BSc in Biochemistry and Physiology (Joint Honours), University of Wales, College of Cardiff.

Career overview

  • 2022 - present: Principal Research Fellow, Centre for Trials Research, Cardiff University.
  • 2020 - present: Deputy Director of Infections, Inflammation and Immunity Trials, Centre for Trials Research, Cardiff University.
  • 2019 - 2022: Senior Research Fellow, Centre for Trials Research, Cardiff University.
  • 2011 - 2019: Research Fellow (Senior Trial Manager), Centre for Trials Research, Cardiff University.
  • 2010 – 2011: Acting Research Fellow (Senior Trial Manager), South East Wales Trials Unit, Cardiff University
  • 2009 – 2010: Research Associate (Trial Manager), South East Wales Trials Unit, Cardiff University.
  • 1999 – 2008: Senior Scientist, Molecular Light Technology (GenProbe Inc.), Cardiff
  • 1997 – 1999: Research Associate, School of Biosciences, University of Wales, Cardiff.

External Committees

  • Current board member for NIHR Programme Grant for Applied Research Committee
  • Previous board member for the Health and Care Research Wales Research for Patient and Public Benefit (RfPPB) panel (2018 to 2024)
  • Previous associate board member for NIHR HTA Commissioning Committee (2023-2024)
  • Previous independent member for several TSCs

Professional memberships

  • Member of the Society for Academic Primary Care (SAPC).
  • Member of BSAC

Committees and reviewing

  • Grant reviewer for the Health and Care Research Wales Research for Patient and Public Benefit (RfPPB),  NIHR School of Primary Care Research
  • Grant reviewer for Cardiff Univeristy MRC Confidence in Concept and MRC Proximity to Discovery funding awards
  • Member of Cwm Taf Research and Development Committee
  • Member of HCRW Primary Care Research Strategy Committee
  • Steering committee member for South West Hub Research Forum
  • Journal reviewer for the BMJ, BMJ Open, British Journal of General Practice, Trials, and BMC Series (Infectious Diseases, Family Practice).

Supervisions

I am interested in supervising PhD students in the areas of:

  • Biomarker guided antimicrobial decision making
  • Antimicrobial resistance
  • Clinical trials methodology

Contact Details

Email Thomas-JonesE@cardiff.ac.uk
Telephone +44 29206 87520
Campuses Neuadd Meirionnydd, Floor 7th Floor, Room 708F, University Hospital of Wales, Heath Park, Cardiff, CF14 4YS